ArticleJournal of nanobiotechnology2026
Activatable nanoflytrap achieves synergistic "Capture-Block-Regulate" therapy of pancreatic ductal adenocarcinoma.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most refractory malignancies because of its dense stromal barrier and hypoxic microenvironment. Inspired by the Venus flytrap, we engineered an intelligent nanoflytrap (NT) system that performs a coordinated three stage therapeutic strategy of capture, block, and regulate for precise and sequential treatment. In the capture stage, the CGKRK containing tumor homing peptide enables dual recognition of p32 receptors that are overexpressed on tumor vasculature and PDAC cells, ensuring selective accumulation within the tumor microenvironment. The ROS responsive PLGA-TK-PEI copolymer further guarantees confined activation under oxidative stress. During the block stage, ROS triggered disassembly of NT releases the pro apoptotic peptide
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.